Portus Wealth Advisors LLC Has $81,000 Stake in AbbVie Inc. $ABBV

Portus Wealth Advisors LLC reduced its stake in shares of AbbVie Inc. (NYSE:ABBV) by 88.7% in the first quarter, HoldingsChannel.com reports. The firm owned 371 shares of the company’s stock after selling 2,902 shares during the period. Portus Wealth Advisors LLC’s holdings in AbbVie were worth $81,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of ABBV. Chelsea Counsel Co. bought a new stake in shares of AbbVie in the 3rd quarter worth $26,000. Litman Gregory Wealth Management LLC bought a new position in shares of AbbVie during the fourth quarter valued at about $28,000. Westend Capital Management LLC bought a new position in shares of AbbVie during the fourth quarter valued at about $29,000. Imprint Wealth LLC boosted its holdings in AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares during the last quarter. Finally, Texas Capital Bancshares Inc TX bought a new stake in AbbVie in the 3rd quarter worth about $31,000. Institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the stock. BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday. William Blair restated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Bank of America upgraded AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 target price on the stock in a research note on Thursday, April 30th. Finally, Evercore set a $235.00 price target on shares of AbbVie in a research report on Friday, May 15th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $253.81.

AbbVie Price Performance

NYSE:ABBV opened at $251.52 on Monday. The company has a market capitalization of $444.38 billion, a P/E ratio of 123.90, a P/E/G ratio of 0.77 and a beta of 0.32. The business has a fifty day simple moving average of $215.16 and a two-hundred day simple moving average of $219.16. AbbVie Inc. has a 1 year low of $181.73 and a 1 year high of $253.35.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. The firm had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.46 EPS. As a group, analysts anticipate that AbbVie Inc. will post 14.28 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is currently 340.89%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said the FDA approved Skyrizi for pediatric use in psoriatic disease, making it the first and only IL-23 inhibitor in the U.S. approved for children six years and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis. The expansion broadens the drug’s addressable market and supports long-term sales growth. Article: SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
• Positive Sentiment: AbbVie’s Apogee Therapeutics acquisition is being viewed favorably by analysts, with Canaccord raising its price target and saying the deal strengthens AbbVie’s long-term growth outlook by adding promising pipeline assets. Article: AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.
• Positive Sentiment: AbbVie is also benefiting from broader healthcare sector strength, with shares hitting new highs as investors rotate into defensive large-cap pharma names. Article: Lilly, J&J, AbbVie hit all-time highs as healthcare outperforms
• Neutral Sentiment: AbbVie announced it will host its second-quarter 2026 earnings call on July 31, which is a standard investor update and does not by itself change fundamentals. Article: AbbVie to Host Second-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Commentary pieces also highlighted AbbVie’s recent pediatric label expansions in Europe for Skyrizi and Maviret, reinforcing the company’s shift toward earlier-disease and younger-patient growth opportunities. Article: Will AbbVie’s (ABBV) Pediatric Expansions Reveal a Deeper Shift in Its Growth Mix?

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.